Delivery Order SPE2DB22D6029-SPE2DB24FU1HH
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $9,834.47, is for the delivery of ACTIVASE 50 MG VIALS. The contract has a firm fixed price and an ultimate completion date of March 14, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price type, valued at $21,358.51 and running through October 2, 2023. The contract is for the supply of ACTIVASE 100 MG VIALS, a critical medical product. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office division is for the delivery of ACTIVASE 50 MG VIALS medical supplies. The contract, valued at $2,864.71, was issued by the Defense Logistics Agency (DLA) Troop Support Medical, a component of the Department of Defense. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA, valued at up to $999,999,999.00 through December 31, 2025, that serves as the primary vehicle for the company to deliver...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $17,141.52 Firm Fixed Price delivery order is for the supply of ACTIVASE 100 MG VIALS, a critical medical product. The contract has an ultimate completion date of October 25, 2024 and was awarded on October 24, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, is for the delivery of ACTIVASE 100 MG VIALS to the Defense Logistics Agency (DLA). The firm fixed price contract has a ceiling value of $12,009.36 and a completion date of March 15, 2024. The contract is a delivery order and does not have a set-aside designation. Amerisourcebergen Drug Corp holds an Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to...
- This federal contract award is a delivery order issued to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The $2,967.98 firm fixed-price contract is for the supply of 4568791017 ACTIVASE 50 MG VIALS, a medication used in medical treatments. The contract has a performance period through July 16, 2025 and is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant $999,999,999.00...
- This federal contract award, valued at $15,753.67, was granted to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, a delivery order under Indefinite Delivery Contract SPE2DB20D1109, was awarded by the Defense Logistics Agency (DLA) to provide 4555456824 ACTIVASE 100 MG VIALS. The award has a firm fixed price and an ultimate completion date of November 18, 2021. Amerisourcebergen Drug Corp is a subsidiary of the parent company...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider based in Conshohocken, Pennsylvania. The $14,839.85 firm fixed-price delivery order is for ACTIVASE 50 MG VIALS and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $26,439.07 firm fixed-price delivery order is for the supply of 4566293297 ACTIVASE 100 MG VIALS, with a completion date of November 1, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive...
- This federal contract award to Amerisourcebergen Drug Corp is for the delivery of ACTIVASE 100 MG VIALS medical supplies, with a Ceiling Value of $39,119.05. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical...
- SPE2DB22D6029Indefinite Delivery Contract
- SPE2DB22D6029-SPE2DB24FU1HHDelivery Order
This federal contract award, valued at $25,782.39, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corporation's Corporate Office Division. The contract is for the delivery of ACTIVASE 50 MG VIALS, a pharmaceutical product, with a completion date of June 18, 2024. Amerisourcebergen, a large pharmaceutical distribution company, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. This single-award IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense (DoD) worldwide. The company also holds a smaller IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs, valued up to $750,000 through May 2024. This contract award was not set aside and was awarded on a full and open competition basis, highlighting Amerisourcebergen's competitive position in the federal pharmaceutical supply market.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $25.8k | 6/17/24 |